After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Participants who received tirzepatide also had greater improvements in metabolic risk ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product. Eli Lilly (NYSE: LLY) is ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...

Preview in new tab Pharmaceutical giants Eli Lilly ($LLY) and Novo Nordisk ($NVO) are engaged in a head-to-head battle to ...

Patients taking Eli Lilly’s drug to combat obesity, Zepbound, lost more weight than those who took Novo Nordisk’s Wegovy in a ...

Women typically lose more weight on Zepbound and Wegovy than men do. Doctors will probably want to consider detailed results on how the two medicines compare across different types of patients ...